Skip to main content

Table 1 Clinical-Pathological features of HM, HM-like and non-HM groups

From: An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

   HM
(n = 78)
HM-like
(n = 41)
Non-HM
(n = 401)
P value
Stage I 14 (17.9%) 10 (24.4%) 62 (15.5%) NS
II 45 (57.7%) 16 (39.0%) 123 (30.9%) ***
III 14 (17.9%) 13 (31.7%) 125 (31.2%) *
IV 3 (3.8%) 1 (2.4%) 72 (18.0%) ***
No data 2 (2.6%) 1 (2.4%) 19 (4.7%) ***
Location Ascending 50 (64.1%) 21 (51.2%) 115 (28.7%) ***
Transverse 10 (12.8%) 8 (19.5%) 16 (4.0%) ***
Descending 12 (15.4%) 11 (26.8%) 253 (63.1%) ***
No data 6 (7.7%) 1 (2.4%) 17 (4.2%)  
Mutational Burden Median of mutations/Megabase 44.9 3.9 3.5  
MSI-status MSI-H 61 (78.2%) 6 (14.6%) 3 (0.7%) ***
MSS/MSI-L 11 (14.1%) 34 (82.9%) 377 (94.0%) ***
  Indeterminate 6 (7.7%) 1 (2.4%) 21 (5.2%)
Pol-ε exonuclease domain mutation   15 (19.2%) 0 0